Canadian VIGOUR Centre   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Edmonton Canada (1997)

Organization Overview

First Clinical Trial
2003
NCT00121446
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Canadian VIGOUR Centre

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronary Artery Disease (Phase 3)

Coronary Disease (Phase 3)

Heart Failure (Phase 3)

Infarction (Phase 3)

Myocardial Infarction (Phase 3)

Myocardial Ischemia (Phase 3)

ST Elevation Myocardial Infarction (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 7